New Side Effects With AstraZeneca and Janssen COVID-19 Vaccines?

New Side Effects With AstraZeneca and Janssen COVID-19 Vaccines?

TMR is not suggesting to anyone not to access COVID-19 ‘vaccines’. Merely providing information to those who may be at risk, knowingly or otherwise, to be aware that there ARE varying life-threatening risks and to consider and consult, before becoming a ‘negative/positive statistic, all the theories, conspiratorial, truths taken on board. We encourage there is not an earlier time available for everyone to take stock of their health and immunise themselves against all poor health lifestyles.

Medscape Logo
Medical Newsreprint

by Sue Hughes

April 09, 2021

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

In addition to the unusual blood clots linked to the AstraZeneca COVID-19 vaccine, which have received extensive attention in the past couple of weeks, other safety signals are also being investigated with this vaccine, and now with Johnson & Johnson’s Janssen vaccine as well, the European Medicines Agency (EMA) reports.

Highlights of the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) meeting April 6-9 include that the agency has started a review of a safety signal to assess reports of capillary leak syndrome in people who were vaccinated with Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).

It also reports that PRAC has started a review of a safety signal to assess reports of thromboembolic events with low platelets in people who received the COVID-19 Vaccine Janssen.

Capillary Leak Syndrome with AZ Vaccine

An EMA press release issued today notes that five cases of capillary leak syndrome, characterized by leakage of fluid from blood vessels causing tissue swelling and a drop in blood pressure in individuals receiving the AstraZeneca vaccine, were reported in the EudraVigilance database.

“At this stage, it is not yet clear whether there is a causal association between vaccination and the reports of capillary leak syndrome. These reports point to a ‘safety signal’ — information on new or changed adverse events that may potentially be associated with a medicine and that warrants further investigation,” the EMA states.

PRAC will evaluate all the available data to decide if a causal relationship is confirmed or not, it adds.

Thromboembolic Events with J&J/Janssen Vaccine

Four serious cases of unusual blood clots with low blood platelets have been reported postvaccination with COVID-19 Vaccine Janssen, EMA reports. One case occurred in a clinical trial and three cases occurred during the vaccine rollout in the US. One of them was fatal.

COVID-19 Vaccine Janssen is currently only used in the US, under an emergency use authorization. COVID-19 Vaccine Janssen was authorized in the EU on March 11. The vaccine rollout has not started yet in any EU member state but is expected in the next few weeks.

The Janssen vaccine uses an adenovirus vector, as does the AstraZeneca vaccine.

PRAC is investigating these cases and will decide whether regulatory action may be necessary, which usually consists of an update to the product information, it adds.

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn

Additional ‘educational’ reading: https://www.medscape.org/viewarticle/948301

Leave a Reply

Please Support The Montserrat Reporter

This is bottom line for us! Unless we receive your support, our effort will not be able to continue. Whatever and however you can, please support The Montserrat Reporter in whatever amount you can (and whatever frequency) – and it only takes a minute.
Thank you

TMR print pages

Newsletter

Archives

CARICOM – Staff Vacancy

CXC HEADQUARTERS - Executive Search

https://indd.adobe.com/embed/2b4deb22-cf03-4509-9bbd-938c7e8ecc7d

A Moment with the Registrar of Lands

New Side Effects With AstraZeneca and Janssen COVID-19 Vaccines?

TMR is not suggesting to anyone not to access COVID-19 ‘vaccines’. Merely providing information to those who may be at risk, knowingly or otherwise, to be aware that there ARE varying life-threatening risks and to consider and consult, before becoming a ‘negative/positive statistic, all the theories, conspiratorial, truths taken on board. We encourage there is not an earlier time available for everyone to take stock of their health and immunise themselves against all poor health lifestyles.

Medscape Logo
Medical Newsreprint

by Sue Hughes

April 09, 2021

Insert Ads Here

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

In addition to the unusual blood clots linked to the AstraZeneca COVID-19 vaccine, which have received extensive attention in the past couple of weeks, other safety signals are also being investigated with this vaccine, and now with Johnson & Johnson’s Janssen vaccine as well, the European Medicines Agency (EMA) reports.

Highlights of the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) meeting April 6-9 include that the agency has started a review of a safety signal to assess reports of capillary leak syndrome in people who were vaccinated with Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).

It also reports that PRAC has started a review of a safety signal to assess reports of thromboembolic events with low platelets in people who received the COVID-19 Vaccine Janssen.

Capillary Leak Syndrome with AZ Vaccine

An EMA press release issued today notes that five cases of capillary leak syndrome, characterized by leakage of fluid from blood vessels causing tissue swelling and a drop in blood pressure in individuals receiving the AstraZeneca vaccine, were reported in the EudraVigilance database.

“At this stage, it is not yet clear whether there is a causal association between vaccination and the reports of capillary leak syndrome. These reports point to a ‘safety signal’ — information on new or changed adverse events that may potentially be associated with a medicine and that warrants further investigation,” the EMA states.

PRAC will evaluate all the available data to decide if a causal relationship is confirmed or not, it adds.

Thromboembolic Events with J&J/Janssen Vaccine

Four serious cases of unusual blood clots with low blood platelets have been reported postvaccination with COVID-19 Vaccine Janssen, EMA reports. One case occurred in a clinical trial and three cases occurred during the vaccine rollout in the US. One of them was fatal.

COVID-19 Vaccine Janssen is currently only used in the US, under an emergency use authorization. COVID-19 Vaccine Janssen was authorized in the EU on March 11. The vaccine rollout has not started yet in any EU member state but is expected in the next few weeks.

The Janssen vaccine uses an adenovirus vector, as does the AstraZeneca vaccine.

PRAC is investigating these cases and will decide whether regulatory action may be necessary, which usually consists of an update to the product information, it adds.

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn

Additional ‘educational’ reading: https://www.medscape.org/viewarticle/948301